Eli Lilly's Orforglipron Shows Promising Weight Loss Results in Trials

In-Depth Analysis

Orforglipron is an investigational once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist. The ATTAIN-1 trial (NCT05869903) was a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial that compared the efficacy and safety of orforglipron (6 mg, 12 mg, and 36 mg) as a monotherapy to a placebo in adults with obesity, or overweight with at least one comorbidity, excluding diabetes. The trial randomized 3,127 participants across multiple countries.

The results indicate that orforglipron could potentially transform obesity care by providing a convenient oral alternative to injectable treatments. Eli Lilly plans to submit orforglipron for regulatory review by the end of the year, with a potential launch in 2026. This oral option could help meet the demand for weight loss medications and address supply issues associated with existing injectable drugs, potentially reaching a broader patient population. The convenience of an oral medication could also make more physicians comfortable prescribing GLP-1s.

However, some analysts noted that the weight loss results were slightly lower than anticipated, and some doctors made note of the number of patients on the highest dose of the pill who discontinued treatment due to side effects. Detailed trial results will be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2025 and published in a peer-reviewed journal. More phase three trial results on the pill will be shared later this year, including from a study on adults who have obesity or are overweight and have Type 2 diabetes.

Read source article

FAQ

How does orforglipron work?

Orforglipron is an oral GLP-1 receptor agonist that helps to promote weight loss and regulate blood sugar.

What were the common side effects reported in the trial?

The most commonly reported side effects were gastrointestinal-related, such as nausea, constipation, diarrhea, and vomiting, generally mild-to-moderate in severity.

When will orforglipron be available?

Eli Lilly expects to submit the data to regulators by the end of the year, with plans to launch the pill in 2026.

Takeaways

Orforglipron offers a potential needle-free alternative to injectable weight loss medications.
The drug has demonstrated significant weight loss and improvements in cardiovascular risk factors.
While side effects are a consideration, the convenience of an oral medication may make it a more accessible option for many patients.

Discussion

Do you think orforglipron will become a popular alternative to injectable weight loss medications? Let us know in the comments below!

Share this article with others who need to stay ahead of this trend!

Sources

Eli Lilly's obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for approval Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity Lilly’s Obesity Pill Cut Body Weight by 11% in Key Study

Disclaimer

This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.

All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.

This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.

Always do your own research (DYOR) before making any decisions based on the information presented.